Gain Therapeutics (GANX) Non-Current Assets (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Non-Current Assets of $516696.0 for Q1 2026, up 9.32% year-over-year from $472647.0 in Q1 2025, and down 11.2% quarter-over-quarter from $581837.0 in Q4 2025.
Gain Therapeutics (GANX) Non-Current Assets (2020 - 2026) Analysis & Trends
Gain Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $516696.0 for Q1 2026.
- In Q1 2026, Non-Current Assets rose 9.32% year-over-year to $516696.0; the TTM figure through Mar 2026 stood at $516696.0 (up 9.32% YoY), while the FY2025 annual figure was $581837.0, up 11.59% from the prior year.
- Non-Current Assets for Q1 2026 stood at $516696.0, down from $581837.0 in the prior quarter.
- The five-year high for Non-Current Assets was $6.1 million in Q2 2022, with the low at $454412.0 in Q3 2025.
- The 5-year median for Non-Current Assets is $714661.0 (2024), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 495.07% in 2022, then slumped 84.28% in 2023.
- Gain Therapeutics' Non-Current Assets stood at $3.0 million in 2022, then slumped by 72.39% to $830463.0 in 2023, then tumbled by 37.22% to $521406.0 in 2024, then gained by 11.59% to $581837.0 in 2025, then retreated by 11.2% to $516696.0 in 2026.
- Business Quant data shows GANX's Non-Current Assets at $516696.0 in Q1 2026, $581837.0 in Q4 2025, and $454412.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 452,191.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 452,191.00 |
| Mar 31, 2026 | 516,696.00 |
| Dec 31, 2025 | 581,837.00 |
| Sep 30, 2025 | 454,412.00 |
| Jun 30, 2025 | 527,277.00 |
| Mar 31, 2025 | 472,647.00 |
| Dec 31, 2024 | 521,406.00 |
| Sep 30, 2024 | 624,324.00 |
| Jun 30, 2024 | 657,308.00 |
| Mar 31, 2024 | 714,661.00 |
| Dec 31, 2023 | 830,463.00 |
| Sep 30, 2023 | 855,891.00 |
| Jun 30, 2023 | 952,426.00 |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 3.01 Mn |
| Sep 30, 2022 | 3.98 Mn |
| Jun 30, 2022 | 6.06 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 1.26 Mn |
| Sep 30, 2021 | 1.01 Mn |